Evidence map›Paper›PMID 28599060›Full record

Trial reportClinical pharmacology and therapeutics2018

Evaluation of Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Sacubitril/Valsartan (LCZ696) and Sildenafil in Patients With Mild-to-Moderate Hypertension.

H-L Hsiao, T H Langenickel, J Petruck, K Kode, S Ayalasomayajula, U Schuehly, M Greeley, P Pal, W Zhou, M F Prescott and 2 more

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical pharmacology and therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Sacubitril Ameliorates Cardiac Fibrosis Through Inhibiting TRPM7 Channel.Frontiers in cell and developmental biology · 2021
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 3 countries.

H-L HsiaoTranslational Medicine, Drug Metabolism and Pharmacokinetics, Novartis Institutes for BioMedical Research (NIBR), East Hanover, New Jersey, USA.
T H LangenickelTranslational Medicine, Clinical Pharmacology and Profiling, Novartis Institutes for BioMedical Research (NIBR), Basel, Switzerland.
J PetruckTranslational Medicine, Clinical Sciences and Innovation, Novartis Institutes for BioMedical Research (NIBR), Cambridge, Massachusetts, USA.
K KodeBiostatistical Sciences, Novartis Healthcare Pvt. Ltd., Hyderabad, India.
S AyalasomayajulaTranslational Medicine, Drug Metabolism and Pharmacokinetics, Novartis Institutes for BioMedical Research (NIBR), East Hanover, New Jersey, USA.
U SchuehlyTranslational Medicine, Clinical Pharmacology and Profiling, Novartis Institutes for BioMedical Research (NIBR), Basel, Switzerland.
M GreeleyTranslational Medicine, Clinical Sciences and Innovation, Novartis Institutes for BioMedical Research (NIBR), Cambridge, Massachusetts, USA.
P PalBiostatistical Sciences, Novartis Healthcare Pvt. Ltd., Hyderabad, India.
W ZhouTranslational Medicine, Drug Metabolism and Pharmacokinetics, Novartis Institutes for BioMedical Research (NIBR), East Hanover, New Jersey, USA.
M F PrescottGlobalClinical Development, Novartis Pharmaceuticals Corp., East Hanover, New Jersey, USA.
G SunkaraTranslational Medicine, Drug Metabolism and Pharmacokinetics, Novartis Institutes for BioMedical Research (NIBR), East Hanover, New Jersey, USA.
I RajmanTranslational Medicine, Clinical Pharmacology and Profiling, Novartis Institutes for BioMedical Research (NIBR), Basel, Switzerland.
Novartis (Switzerland) · CHNovartis (India) · INNovartis Institutes for BioMedical Research

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sacubitril/valsartan (LCZ696) is indicated for the treatment of patients with heart failure and reduced ejection fraction (HFrEF). Since patients with HFrEF may receive sacubitril/valsartan and sildenafil, both increasing cyclic guanosine monophosphate, the present study evaluated the pharmacokinetic and pharmacodynamic drug interaction potential between sacubitril/valsartan and sildenafil. In this open-label, three-period, single sequence study, patients with mild-to-moderate hypertension (153.8 ± 8.2 mmHg mean systolic blood pressure (SBP)) received a single dose of sildenafil 50 mg, sacubitril/valsartan 400 mg once daily for 5 days, and sacubitril/valsartan and sildenafil coadministration. When coadministered with sildenafil, the AUC and C

Indexed as

AminobutyratesAngiotensin Receptor AntagonistsAntihypertensive AgentsAtrial Natriuretic FactorBiphenyl CompoundsBlood PressureCyclic GMPDouble-Blind MethodDrug CombinationsDrug InteractionsHumansHypertensionMaleMiddle AgedSildenafil CitrateTetrazolesAminobutyratesAngiotensin Receptor AntagonistsAntihypertensive AgentsAtrial Natriuretic FactorBiphenyl CompoundsCyclic GMPDrug Combinationssacubitril and valsartan sodium hydrate drug combinationSildenafil CitrateTetrazolesValsartan

Identifiers

PMID28599060
PMCPMC5836847
OpenAlexW2623933438

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.